Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial
Authors:
- 27 August 2025
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 12 (9) , e616-e626
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
This publication has 13 references indexed in Scilit:
- GHESKIO's model of patient care during civil unrest in HaitiThe Lancet HIV, 2024
- Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trialThe Lancet HIV, 2024
- Second-Line Switch to Dolutegravir for Treatment of HIV InfectionNew England Journal of Medicine, 2023
- Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialClinical Infectious Diseases, 2022
- Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesisJournal of Clinical Epidemiology, 2022
- Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in HaitiOpen Forum Infectious Diseases, 2021
- Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIVNew England Journal of Medicine, 2021
- Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency VirusClinical Infectious Diseases, 2020
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical TrialsClinical Infectious Diseases, 2019
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialThe Lancet HIV, 2018